Table I.
Lung tumor incidence and tumor multiplicity
| Period in months |
||||||
|---|---|---|---|---|---|---|
| 3 (%) | 6 (%) | 9 (%) | 12 (%) | 9 a (%) | 12 a (%) | |
| Tumor incidence (mice with tumors/total mice) | ||||||
| SP-C/Ki-ras | 10/18 (55) | 14/16 (87) | 13/15 (87) | 7/7 (100) | 2/20 (10) | 0/5 (0) |
| CCSP/Ki-ras | 11/15 (73) | 18/18 (100) | 18/18 (100) | 5/5 (100) | 2/10 (20) | 0/3 (0) |
| Monotrans. +DOX | — | — | 2/20 (10) | — | 2/20 (10) | 2/5 (40) |
| FVB/N | — | — | — | — | — | 0/10 (0) |
| FVB/N + DOX | — | — | — | — | — | 0/9 (0) |
| Tumor multiplicity (number of tumors per mouse) | ||||||
| SP-C/Ki-ras | 1.7 ± 2.0 | 3.9 ± 2.4 | 10.2 ± 7.2 | 12.6 ± 8.2 | 0.2 ± 0.4 | 0.0 |
| CCSP/Ki-ras | 3.5 ± 4.7 | 13.3 ± 3.9 | 28.8 ± 8.7 | 34.0 ± 8.4 | 0.2 ± 0.4 | 0.0 |
| Monotrans. + DOX | — | — | 0.6 ± 0.3 | — | 0.1 ± 0.3 | 0.4 ± 0.4 |
| FVB/N | — | — | — | — | — | 0.0 |
| FVB/N + DOX | — | — | — | — | — | 0.0 |
Mice were treated with 500 μg/ml of DOX for the times indicated.
a
Untreated (DOX naive) control mice.